GlassScriptPhysician profile
Michael J Castine
NPI 1205814092
$164,666.97
in general payments reported to CMS, 2019-2025
87 companies · $3,260 in 2025
The $3,260 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $86K · 2020: $30K · 2021: $22K · 2022: $16K · 2023: $2,973 · 2024: $3,262 · 2025: $3,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,724 · Education: $646 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,723.94 |
| Education | $645.52 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $69,188.06 | 2019-2025 | Ninlaro, Fruzaqla |
| Exelixis INC. | $39,268.26 | 2019-2025 | Cabometyx |
| Alexion Pharmaceuticals, INC. | $25,362.80 | 2019-2025 | Ultomiris |
| Glaxosmithkline, LLC. | $7,304.88 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| E.R. Squibb & Sons, L.L.C. | $4,274.93 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Novartis Pharmaceuticals Corporation | $1,396.57 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $1,237.10 | 2019-2024 | Tavalisse, Rezlidhia |
| Astrazeneca Pharmaceuticals LP | $1,161.63 | 2019-2025 | Calquence, Imfinzi, Enhertu |
| Janssen Biotech, INC. | $1,141.29 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Pfizer INC. | $1,031.67 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $903.06 | 2019-2025 | Keytruda, Welireg, Reblozyl |
| Eusa Pharma (US) LLC | $757.53 | 2019-2020 | |
| Genzyme Corporation | $663.45 | 2019-2025 | |
| Celgene Corporation | $643.92 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Genentech USA, INC. | $560.20 | 2019-2024 | Tecentriq, Polivy, Lunsumio |
Show all 80 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $553.66 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $538.64 | 2019-2025 | |
| Amgen INC. | $536.59 | 2019-2023 | Blincyto, Kyprolis, Lumakras |
| Astellas Pharma US INC | $512.74 | 2019-2025 | Xtandi, Padcev, Vyloy |
| Daiichi Sankyo INC. | $489.91 | 2019-2025 | Enhertu, Datroway |
| Pharmacyclics LLC, An Abbvie Company | $454.19 | 2019-2023 | Imbruvica, Epkinly |
| Ipsen Biopharmaceuticals, INC | $397.98 | 2019-2025 | Somatuline Depot, Onivyde, Tazverik |
| Beigene USA, INC. | $389.07 | 2021-2025 | Brukinsa, Tevimbra |
| Abbvie INC. | $378.87 | 2019-2025 | |
| Eisai INC. | $363.02 | 2019-2025 | |
| Seagen INC. | $322.66 | 2019-2023 | Tukysa |
| Lilly USA, LLC | $319.85 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Incyte Corporation | $315.75 | 2019-2025 | Monjuvi, Jakafi |
| Emd Serono, INC. | $312.62 | 2019-2025 | Bavencio |
| Gilead Sciences, INC. | $311.01 | 2021-2025 | Trodelvy |
| Janssen Pharmaceuticals, INC | $199.03 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $196.54 | 2022-2025 | Empaveli |
| Regeneron Healthcare Solutions, INC. | $176.73 | 2019-2024 | Libtayo |
| Puma Biotechnology, INC. | $169.64 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $164.32 | 2022-2025 | Fotivda |
| Morphosys, US INC. | $156.00 | 2021-2023 | Monjuvi |
| Adaptive Biotechnologies Corporation | $155.10 | 2021-2025 | Clonoseq |
| Karyopharm Therapeutics INC. | $146.09 | 2020-2024 | Xpovio |
| Acrotech Biopharma INC. | $138.66 | 2024 | Beleodaq |
| Sirtex Medical INC | $138.50 | 2020 | |
| Novocure INC. | $134.99 | 2024 | Optune |
| Sobi, INC | $128.23 | 2022-2025 | |
| Pharmacosmos Therapeutics INC. | $118.64 | 2022-2025 | Monoferric |
| Blueprint Medicines Corporation | $106.06 | 2020-2022 | |
| Adc Therapeutics America, INC. | $101.95 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $93.57 | 2021-2025 | |
| Servier Pharmaceuticals LLC | $88.97 | 2024-2025 | |
| Array Biopharma INC | $84.41 | 2020-2025 | Mektovi, Braftovi, Lorbrena |
| Veracyte, INC. | $76.22 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.01 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $73.41 | 2023 | Myrisk |
| Taiho Oncology, INC. | $67.04 | 2023-2025 | |
| Springworks Therapeutics, INC. | $55.37 | 2024-2025 | Ogsiveo |
| Tesaro, INC. | $51.43 | 2019 | |
| G1 Therapeutics, INC. | $51.26 | 2022-2023 | Cosela |
| Syndax Pharmaceuticals, INC. | $48.83 | 2025 | |
| Siemens Medical Solutions USA, INC. | $45.92 | 2024 | Artis Icono Floor |
| Coherus Oncology, INC. | $40.93 | 2023 | |
| Pharmaessentia USA Corporation | $39.47 | 2025 | Besremi |
| Beone Medicines USA, INC. | $39.36 | 2025 | Brukinsa |
| Mirati Therapeutics, INC. | $33.35 | 2023 | Krazati |
| Epizyme, INC. | $32.17 | 2020-2021 | |
| Recordati_rare_diseases_inc. | $30.84 | 2024 | Sylvant |
| Kyowa Kirin, INC. | $30.04 | 2019-2022 | |
| Kite Pharma, INC. | $24.64 | 2020-2021 | |
| Medtronic USA, INC. | $23.88 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $22.22 | 2019 | |
| Agios Pharmaceuticals, INC. | $22.18 | 2025 | Pyrukynd |
| Acceleron Pharma, INC. | $19.69 | 2021 | |
| Alnylam Pharmaceuticals INC. | $18.67 | 2023 | Givlaari |
| Advanced Accelerator Applications | $18.15 | 2019 | |
| Cti Biopharma Corp. | $17.84 | 2023 | Vonjo |
| Amag Pharmaceuticals, INC. | $16.99 | 2019 | |
| Tg Therapeutics, INC. | $16.53 | 2021 | |
| Secura Bio, INC. | $15.93 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $14.96 | 2021 | |
| Organon LLC | $14.77 | 2024 | |
| Verastem, INC. | $14.69 | 2019 | |
| Clovis Oncology, INC. | $13.68 | 2019 | |
| Pharmaand Gmbh | $13.16 | 2025 | Rubraca |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$61.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Castine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.